Ambros Therapeutics, Inc.
PrivateLast Round
Series A
Dec 16, 2025
Total Funding Raised
$125M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Ambros Therapeutics, Inc. operates in Healthcare & Life Sciences and is based in Irvine, California. Its latest recorded funding round was a Series A round in December 2025.
Ambros Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development of innovative and transformative medicines for diseases with a high unmet medical need, with its lead program targeting complex regional pain syndrome type 1 (CRPS-1).
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Ambros Therapeutics, Inc. Comparables
Compare Ambros Therapeutics, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Axsome Therapeutics Inc | 74% | |
| Abiogen Pharma | 64% | |
| Plumeria Therapeutics, Inc. | 61% |
For institutional investors. Book with your work email.
Ambros Therapeutics, Inc. Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Ambros Therapeutics, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Enavate Sciences | Series A |
| Janus Henderson Group | Series A |
| Balyasny Asset Management L.P. | Series A |
| RA Capital Management | Series A |
| Adage Capital Partners, L.P. | Series A |
| Adage Capital Management | Series A |
| Transhuman Capital | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 3, 2026
Grew 19% QoQ, from 32 to 38 employees.
- Sep 12, 2026
Monthly visitors grew 40% MoM, reaching 4K.
For institutional investors. Book with your work email.
Ambros Therapeutics, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Ambros Therapeutics, Inc.'s valuation, stock price, and market status.
Is Ambros Therapeutics, Inc. a public or private company?
Ambros Therapeutics, Inc. is a private company.
What is the current stock price of Ambros Therapeutics, Inc.?
Ambros Therapeutics, Inc. is a private company, so its shares have no public market price. Caplight tracks Ambros Therapeutics, Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Ambros Therapeutics, Inc. worth (valuation)?
Valuation information for Ambros Therapeutics, Inc. is not publicly available.
Can I buy Ambros Therapeutics, Inc. stock?
Ambros Therapeutics, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Ambros Therapeutics, Inc.'s last funding round?
Ambros Therapeutics, Inc.'s most recent funding round was Series A on December 16, 2025.
Who are the main investors in Ambros Therapeutics, Inc.?
Key investors in Ambros Therapeutics, Inc. include Enavate Sciences, RA Capital Management.
Will Ambros Therapeutics, Inc. IPO soon?
No public IPO plans have been announced for Ambros Therapeutics, Inc..
How can I track Ambros Therapeutics, Inc. secondary market activity?
Caplight tracks bids, offers, and trades in Ambros Therapeutics, Inc.'s shares on secondary markets.